Sandbox Reserved 687
From Proteopedia
(Difference between revisions)
Line 3: | Line 3: | ||
<!-- PLEASE ADD YOUR CONTENT BELOW HERE --> | <!-- PLEASE ADD YOUR CONTENT BELOW HERE --> | ||
- | == | + | ==Complera: Emtricitabine/rilpivirine/tenofovir== |
* Marketed by: Gilead Sciences and Janssen Therapeutics | * Marketed by: Gilead Sciences and Janssen Therapeutics |
Revision as of 20:43, 2 May 2013
This Sandbox is Reserved from 30/01/2013, through 30/12/2013 for use in the course "Biochemistry II" taught by Hannah Tims at the Messiah College. This reservation includes Sandbox Reserved 686 through Sandbox Reserved 700. |
To get started:
More help: Help:Editing |
Complera: Emtricitabine/rilpivirine/tenofovir
- Marketed by: Gilead Sciences and Janssen Therapeutics
- Major Indication: HIV infection
- Drug Class: Combination of nucleoside/tide reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor
- Date of FDA Approval: August 2011
Rilpivirine (RPV)
|
RPV in the In red are the binding pocket residues p66 (Leu-100, Lys-101, Lys-103, Val-106, Thr-107, Val-108, Val-179, Tyr-181, Tyr-188, Val-189, Gly-190, Phe-227, Trp-229, Leu- 234, and Tyr-318) and p51(Glu-138). Singh et al.
|
Reverse Transcriptase:
Emtricitabine Image:Emtricitabine3.png
|